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Abstract
Background: The association between colorectal cancer (CRC) and smoking has not been consistent. Incomplete
smoking history and association to a specific subset of CRC tumors have been proposed as explanations. The
adenomatous polyposis coli (APC) gene has been reported to have a "gatekeeper" function in the colonic mucosa.
Methods: To evaluate the hypothesis that cigarette smoking is associated with adenoma and carcinoma development
and further to investigate whether this association is due to mutations in the APC gene, we used a study population
consisting of 133 cases (45 adenomas and 88 carcinomas) and 334 controls. All tumors were sequenced in the mutation
cluster region (MCR) of the APC gene. Cases and controls were drawn from a homogeneous cohort of Norwegian origin.
Results: The mutational spectra of the APC gene revealed no difference in frequencies of mutations in cases based on
ever and never smoking status. An overall case-control association was detected for adenomas and "ever smoking" OR
= 1.73 (95% CI 0.83–3.58). For CRC cases several smoking parameters for dose and duration were used. We detected
an association for all smoking parameters and "duration of smoking > 30 years", yielded a statistically significant OR =
2.86 (1.06–7.7). When cases were divided based on APC truncation mutation status, an association was detected in
adenomas without APC mutation in relation to "ever smoking", with an OR = 3.97 (1.26–12.51). For CRC cases without
APC mutation "duration of smoking > 30 years", yielded a statistically significant OR = 4.06 (1.20–13.7). The smoking
parameter "starting smoking ≥ 40 years ago" was only associated with CRC cases with APC mutations, OR = 2.0 (0.34–
11.95). A case-case comparison revealed similar findings for this parameter, OR = 2.24 (0.73–6.86).
Conclusion: Our data suggest an association between smoking and adenoma and CRC development. This association
was strongest for cases without APC truncation mutation. This may implicate other factors in development of these
tumors. The association detected between smoking and CRC cases with APC mutation was in relationship to the smoking
parameter "starting smoking ≥ 40 years ago", a time period long enough to proceed CRC initiation.
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Background
Development of sporadic colorectal adenomas and carci-
nomas has been associated with several lifestyle factors,
including cigarette smoking [1,2]. Cigarette smoke con-
tains a large number of carcinogens, which may bind to
DNA and form adducts, potentially causing irreversible
genetic damage in the normal colorectal mucosa [3-5].
The large bowel is exposed to these compounds through
the circulatory system [1], and it has been proposed that
the first hit in colorectal cancer (CRC) development is
most likely caused by blood-borne carcinogens in the
colonic crypt [6]. This makes carcinogens from tobacco
smoke a potential source. A number of case control stud-
ies have shown a strong correlation between cigarette
smoking and the risk of developing adenomas, but the
evidence linking cigarette smoking and CRC has been
inconsistent [1]. Cigarette smoking as the initial cause of
CRC may require a smoking history as long as 40 years
[1,7]. In studies conducted prior to 1970 only a limited
number of smokers would have exceeded four decades of
smoking. This has been proposed as an explanatory factor
for the inconsistent results in linking cigarette smoking to
CRC development [1].
Another explanation for this discrepancy is that cigarette
smoking is only involved in tumors with specific genetic
mutations. So far, the genetic targets of carcinogens from
cigarette smoking in CRC development have not been
fully elucidated. It is possible that several genes in differ-
ent molecular pathways are affected. CRC development
may take at least two different pathways based on
genomic instability. The majority of sporadic cases display
chromosomal instability (CIN) while microsatellite insta-
bility (MSI) with mutations in mismatch repair genes is
displayed in about 15% [8]. CRC tumors displaying MSI
have been positively associated with cigarette smoking in
four studies while one study detected no such association
[9-13]. The CIN pathway involves mutations in several
genes including adenomatous polyposis coli (APC), k-ras
and TP53. As a target gene for initiation, APC fits the pro-
file with its "gatekeeper" function in the colonic mucosa
[14-16]. APC is a tumor suppressor gene in the Wnt sign-
aling pathway, and it regulates cell proliferation mainly
through its association with β-catenin [17]. Mutations in
the APC gene have been detected in the majority of ade-
noma and CRC cases [16,18-23]. The so called "mutation
cluster region" (MCR), codons 1286 – 1513, represents
<10% of the APC gene, but previous studies have shown
that as much as 60–70% of the somatic mutations occur
in this region [20,21,24,25]. A truncation mutation in the
MCR region of the APC gene will result in a protein that
lacks most of its 20-amino acids β-catenin binding and
down regulation sites.
Only two case-control studies have to our knowledge
investigated the association between cigarette smoking
and  APC  truncation mutations in CRC development
[10,11]. They reported no association when focusing on
"ever smoking", "starting smoking > 35 years ago", "high
dose or long duration", but interestingly they detected an
inverse association for "starting smoking < 35 years ago"
[11], and "first starting smoking after age 25" [10]. A
smoking parameter of "years since starting smoking",
which precedes the initiating point for CRC development,
might therefore be important when evaluating APC muta-
tion and CRC risk.
Most studies have focused on truncation mutations. Even
though the biological significance of missense and silent
mutations are uncertain, the mutational spectra of the
APC gene may provide a more complete picture of impact
and type of carcinogenic exposure.
In this Norwegian case-control study, the KAM cohort, we
used direct sequencing of the APC MCR to evaluate the
mutational spectra of the gene in relation to smoking his-
tory in both colorectal adenomas and carcinomas. We
also investigated the overall adenoma and CRC risk in
association with several smoking parameters. The same
investigation was further conducted after dividing the case
groups based on APC truncation mutation status with a
particular focus on CRC and years since starting smoking.
Methods
The KAM cohort (Kolorektal cancer, Arv og Miljø) is based
on the screening group of the Norwegian Colorectal Can-
cer Prevention study (The NORCCAP study) in Telemark
[26], and a series of colorectal cancer cases from the same
region (Telemark) operated on at Telemark Hospital in
Skien. The KAM biobank has previously been described
[27]. The KAM cohort is based on an ethnic homogeneous
group of Norwegian origin. The ID number for the
NORCCAP study at Clinicaltrials.gov is – I NCT00119912
[28]. Those invited to participate in the NORCCAP study
were 20,780 men and women, age 50–64 years old, drawn
by randomization from the population registry. The over-
all attendance rate was 65%. The 48 adenoma cases with
severe degree of dysplasia and a control group of 334 indi-
viduals were drawn from the NORCCAP study. All the
controls in the KAM cohort that completed the question-
naire were included. The controls were screen negative
participants (negative flexible sigmoidoscopy). For CRC
cases, all patients diagnosed with colorectal cancer who
were mentally competent to complete the questionnaire
were asked to participate in the KAM study. The question-
naire contained information on a family history of cancer
and the included CRC cases had no known personal his-
tory of cancer. In this study 94 CRC cases were drawn from
the KAM cohort. The tumor histology of the carcinomasBMC Cancer 2006, 6:71 http://www.biomedcentral.com/1471-2407/6/71
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and adenomas was examined independently by two spe-
cialist histopathologists in order to determine the tumor
stage. The Regional Ethics Committee and the Data
Inspectorate have approved the KAM study.
Sequencing was performed on DNA isolated from forma-
lin-fixed, paraffin-embedded colon tumor tissue, col-
lected prior to chemo- or radiotherapy treatment (> 60%
tumor cells) using a GenoPrep™ DNA Isolation from Tis-
sue kit (GenoVision). The analysis covers codons 1260 –
1585, including all the codons in the extended MCR, res-
idues 1281 – 1556 [29]. The reference sequence for
human APC is Genbank Accession Number M74088. The
MCR region was divided into five overlapping fragments
and amplified separately in two consecutive PCRs. The
first fragment is 297 bp, codons 1260 – 1358. The PCR
primers are: Fragment 1.1: (1246–1358) forward – AAGT-
GGTCAGCCTCAAAAGG, reverse – CGCTCCTGAA-
GAAAATTCAAC, and fragment 1.2: (1260–1358) forward
– CAGACTTATTGTGTAGAAG, reverse CGCTCCTGAA-
GAAAATTCAAC. The PCR reaction mixture (total volume
50 µl) contained 50 ng DNA, 0.4 µM of each primers, 0.2
mM dNTP's, 1× PCR buffer, 2–3 mM MgCl2 and 0.5 U Taq
DNA polymerase. The reaction conditions for the first
PCR: Fragment 1.1: 5 cycles of 30 s at 94°C, 45 s at 56°C,
1 min 70°C, followed by 25 cycles of 30 s at 94°C, 45 s at
54°C, 1 min 70°C followed by 5 min at 70°C. The prim-
ers and reaction conditions for the second PCR and
remaining four fragments, each 220 bp long, and primers
and reaction conditions have been described elsewhere
[18]. All products from the five different fragments were
purified with Min Elute PCR Purification Kit (Qiagen)
before sequencing. The sequencing was performed on ABI
310 automatic sequencer using Big Dye Terminator v 1.1
Cycle Sequencing kit (Applied) by standard protocol and
primers from the second PCR. In 10 of the CRC cases and
8 of the adenoma cases one or more fragments of the
sequenced region of the APC gene could not be amplified.
Some of these cases had mutations in the amplified frag-
ments and these mutations were included in evaluating
the mutational spectra of the gene. For case-control com-
parison all cases with detected truncation mutation were
used. Cases that showed no mutations and or failed in
amplification were left out of the data analysis.
In order to validate the sensitivity of our sequence analysis
of paraffin-embedded tissues, we compared analysis per-
formed on the same samples using DNA from both blood
and paraffin-embedded tissue on a specific region of the
APC gene. The G4497A silent polymorphism is located in
the MCR of APC. We used the amplified products from
fragment 4.2 and the restriction enzyme BtgI to cut the
wild type allele in order to identify samples that were
homozygot for the wild type and the polymorphism,
respectively. The cutting conditions were 1× NE-buffer,
0.3 mM BtgI with a total volume of 11 µl and 4 µl of PCR
product. The samples were incubated over night at 37°C.
The detection limit of the mutational analysis was deter-
mined by mixing the homozygous PCR product for the
polymorphic allele with increasing concentrations of the
Table 1: Distribution of selected characteristics by case-control status.
Cases
Characteristics Controls n = 334 Adenoma cases n = 45 CRC cases n = 88
Mena 129 (39%) 29 (65%) 53 (60%)
Womena 205 (61%) 16 (35%) 35 (40%)
Mean age at cohort entryb 54.3 ± 3.4 57.5 ± 3.6 68.1 ± 9.7
Mean body mass index. kg/mb 26.05 ± 3.7 27.2 ± 5.7 25.0 ± 3.8
Smoking parameters*
Ever smokedc 53% (177/334) 73% (32/44) 67% (56/83)
Mean no. of cigarettes per dayc 10.64 ± 7.3 13.1 ± 6.5 12.7 ± 8.7
Mean no. of years of smokingc 22.0 ± 11.3 33.6 ± 10.3 33.3 ± 15.0
Mean years since starting 
smokingd
34.3 ± 6.8 39.2 ± 6.2 47.0 ± 8.7
*Missing values for smoking parameters gave rise to diminished numbers of cases.
aThere are significant differences in no. of males and females among the control group and the adenoma and CRC case groups, P = 0.001 and < 10-
4 respectively, but no difference between the two case groups P = 0.64.
bThere are significant differences in age between the control group and both of the case groups, and between the adenoma and CRC case groups, 
P < 10-4.
cThere are significantly more ever smokers in the adenoma and CRC case groups compared to the controls, P = 0.013 and 0.017, respectively, but 
no significant difference between the case groups P = 0.54. There is no significant difference between the control group and the adenoma and CRC 
case groups in number of cigarettes smoked per day, P = 0.07 and 0.15, respectively. There are significant differences between the control group 
and both of the case groups for duration of smoking P < 10-4.
dThere are significant differences in years since starting smoking between the control group and both of the case groups, and also between the 
adenoma and CRC case groups, P < 10-4.BMC Cancer 2006, 6:71 http://www.biomedcentral.com/1471-2407/6/71
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corresponding wild type allele, and sequencing these mix-
tures on the ABI 310 as described for the samples.
All of the participants were requested to fill in a self-
administered questionnaire on dietary and personal his-
tory, including smoking habits and family history of can-
cer. Smoking habits were assessed as current smoking
status, number of cigarettes smoked per day, total number
of years smoked, age of starting smoking, and if applicable
the age at which the participant stopped smoking [30-32].
Differences in characteristics between groups were
assessed using the χ2test for categorical variables and the
Mann-Whitney test for continuous variables; p values <
0.05 were considered significant. We examined by logistic
regression the association between smoking and develop-
ment of colorectal adenomas and carcinomas measured
separately as odds ratio (OR) with 95% confidence inter-
val (CI). The controls used as a reference group in this
study of adenomas and carcinomas are matched to the
cases by region (Telemark). An overall case-control com-
parison was conducted as well as separately comparing
cases with or without APC truncation mutation (APC +
and APC -, respectively), to the polyp-free controls in rela-
tionship to smoking history. Case-case comparison was
conducted to evaluate heterogeneity in risk factors. The
risk factors evaluated were: cigarette smoking status
(never, ever), number of cigarettes smoked per day (≤15;
> 15), duration of smoking in years (≤ 30; > 30), and years
since first starting smoking (≥ 40 years ago). MiniTab Sta-
tistical Software, Release 13.1 Xtra (Minitab Inc.) was used
for statistical calculations. The data are age and sex
adjusted.
Results
Study population
Selected characteristics of the controls, and all cases with
satisfactory amplification and mutation analysis of the
APC are given in Table 1.
Mutation analysis
The sensitivity of the mutational analysis, sequenced on
the ABI 310-genetic analyzer, was independent of whether
the DNA originated from blood or paraffin-embedded tis-
sue. We were able to detect the polymorphic allele at 20%
polymorphic PCR product in a background of wild-type
PCR product.
APC mutations were detected in 55% of the adenomas
(25/45) and in 51% of the CRC tumors (45/88). APC
truncation mutations were detected in 40% of the adeno-
mas (18/43) and in 32% of the CRC tumors (27/84),
respectively. Only 10 of the tumors (5 adenomas and 5
CRC, respectively) had more than one mutation detected.
Table 2: APC mutational spectra detected in all adenoma/CRC cases, and cases divided according to smoking status.
Type of mutationa All cases n = 133 
Total number of 
mutations
Ever smokers*b n = 88 Never smokers*b n = 39
Silent/missense 
mutation
Truncation mutation Silent/missense 
mutation
Truncation mutation
Transitions 31(39%) 13 (72%) 7 (25%) 7 (50%) 2 (13%)
C → T 1 7 2742
G → A 96-3-
A → G 44---
T → C 11---
Transversion 21(26%) 5 (28%) 5 (18%) 7 (50%) 2 (13%)
A → C -----
T → G 21-1-
A → T1 - 1 - -
T → A 42-2-
C → A 312--
G → T 61212
C → G --- -
G → C3 - - 3 -
Frameshift 28 (35%) - 16 (57%) - 11 (74%)
T o t a l 8 01 82 81 41 5
*Missing values for ever and never smoking gave rise to diminished numbers of cases and mutations.
a The frequency is calculated by dividing the number of transitions, transversions and framshift mutations separately to the total number of either 
silent/missens or truncated mutations for ever and never smokers.
bThere is no significant difference between ever smokers and never smokers in relation to the mutational spectra (transitions, transversions and 
frameshift) for missens/silent or truncated mutations P = 0.094 and 0.558, respectively.BMC Cancer 2006, 6:71 http://www.biomedcentral.com/1471-2407/6/71
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None of the tumors had more than two mutations
detected. A polymorphism ACG → ACA (G4497A) which
does not alter the amino acid (threonine) was observed in
71% (32/45) of the adenoma cases and 71% (62/88) of
the CRC cases, respectively.
The number of cases with mutations according to ever and
never smoking status are 44/88 (50%) and 22/39 (56%),
respectively. Some of these cases may have more than one
mutation. Type and distribution of all detected mutations
are displayed in Table 2. All mutations are displayed
together since we detected no statistical significant differ-
ence between the adenoma and CRC case groups in rela-
tion to frequency and mutational spectra (data not
shown).
Characteristics of the adenoma and CRC cases with or
without truncation mutations only are given in Table 3.
Case-control
Ever smoking was not significantly associated with
increased overall adenoma risk (see Table 4). When divid-
ing the adenoma case group based on APC truncational
status "ever smoked" was significanly associated with APC
- adenomas only, OR = 3.97.57 (CI 1.26–12.51). Due to
small sample size of the adenoma case group, statistics for
the other smoking parameters were not calculated.
"Duration of smoking > 30 years" was statistically signifi-
cantly associated with increased overall CRC risk, OR 2.86
(1.06–7.7). For CRC cases divided based on APC trunca-
tion mutation status all the smoking characteristics, exept
for "starting smoking ≥ 40 years ago", yielded a higher
odds ratio for APC - tumors compared to APC + tumors
(see Table 5).
Discussion
In this study direct sequencing was used to identify adeno-
mas and CRC tumors with or without any APC mutations
in the MCR region of the gene, and the results were com-
pared to history of smoking. The overall adenoma and
CRC risk as well as cases divided based on APC truncation
mutation status, were assessed according to several smok-
ing parameters.
We detected fewer APC silent/missens mutations than a
resent Dutch study did [33], but the frequencies of trun-
cated mutations detected for CRC and adenomas are com-
Table 3: Distribution of selected smoking characteristics for adenoma and carcinoma cases divided by APC truncation-mutation 
status.
Cases*
Adenomas Carcinomas
Characteristicsa APC+ (n = 18) APC- (n = 25) APC+ (n = 27) APC- (n = 57)
Ever smoked 59% (10/17) 84% (22/26) 68% (17/25) 68% (37/54)
Mean no. cigarettes per day 10,5 ± 5,3 14.5 ± 7,4 11,3 ± 10,0 13,5 ± 8,4
Mean years smoking 39,2 ± 4,6 30,9 ± 11,5 32,4 ± 15,2 34,2 ± 15,1
Mean years since started smoking 40,3 ± 4,8 38,9 ± 6,9 48,9 ± 6,2 46,3 ± 9,8
Starting smoking ≥ 40 years ago 60% (6/10) 45% (10/22) 100%(17/17) 69% (25/36)
*Uncertain APC truncation mutation status for one or more of the sequenced fragments gave rise to diminished numbers of CRC and adenoma 
cases, compared to the study population in Table 1.
aNone of the smoking parameters were significantly different within the adenoma group. Within the CRC group only "starting smoking ≥ 40 years 
ago" yielded a significant difference, P = 0.010.
Table 4: Adenomas, smoking history and APC truncation mutation status.
Smoking parametersa All adenomasb versus 
controls
APC+ versus controls APC- versus controls APC+versus APC-
Never smoked§
Case/control 13/157 *6/157 *4/157 6/4
Ever smoked
Case/control 34/177 *11/177 *22/177 11/22
OR (95% CI) 1.73 (0.83–3.58) 0.96 (0.33–2.85) 3.97 (1.26–12.51) 0.24 (0.05–1.11)
*Missing values for "ever smoked" gave rise to diminished numbers of adeoma cases.
§ Never smoked serves as the reference category.
aAll the OR's are adjusted for age and sex.
bFor overall case-control comparison of adenoma status and smoking all the selected adenoma cases from the study population that had completed 
the questionnaire for smoking parameters were used 47/48.BMC Cancer 2006, 6:71 http://www.biomedcentral.com/1471-2407/6/71
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parable to published studies on APC  truncation
mutations (30–45%) [11,16,18,21,23,33]. The location
and type of mutations detected (data not shown) are also
consistent with those reported in the APC database [34].
The KAM study is to the best of our knowledge the first
study to evaluate the association between colorectal ade-
nomas, APC mutations and smoking history, and also to
evaluate the complete mutational spectra of APC in CRC
cases in relation to smoking history.
We detected no significant difference between the ade-
noma and CRC case groups, or between ever and never
smokers in relation to frequency and type of mutation. A
Japanese study reported similar APC truncation mutations
frequencies [35]. With the exception of one A → T trans-
version all the truncated point mutations detected were
G:C → T:A transversions and C → T transitions. The silent/
missense mutations displayed a more heterogenous
mutational spectra.
For overall case-control comparison a statistically signifi-
cant association was detected for CRC cases and "duration
of smoking > 30 years", OR = 2.86 (CI 1.06–7.7). The fact
that the CRC cases and controls have not been matched by
age may affect the result of the analysis, but the result is
comparable to other studies published in recent years [1].
The selection of controls is vital, and our controls have all
been screened in the colon and found to be polyp free at
flexible sigmoidoscopy. It has been estimated that the risk
of erroneously classifying individuals with proximal
advanced neoplasia as neoplasia-free is less than 3% at
flexible sigmoidoscopy [36]. No significant association
was observed for adenomas and smoking history. This
may be due to low sample size.
When dividing adenoma cases based on APC truncation
mutation status a statistically significant association was
detected for "ever smoked" and APC- adenomas only. This
implies the involvment of other genes in association with
cigarette smoking and adenoma development. Both the
MSI pathway and other CIN genes such as k-ras have pre-
Table 5: Colorectal cancer, smoking history and APC truncation mutation status.
Smoking Parameters a CRC cases versus controls b APC+ versus controls APC- versus controls APC+ versus APC-
Never smoked§
Case/control 30/157 *8/157 *17/157 8/17
Ever smoked
Case/control 58/177 *17/177 *37/177 17/37
OR (95% CI) 1.46 (0.63–3.36) 0.54 (0.09–3.24) 2.31 (0.81–6.60) 0.82 (0.26–2.60)
≤15 cigarettes smoked per 
day
Case/control 42/137 *13/137 *26/137 13/26
OR (95% CI) 1.32 (0.55–3.16) 0.08 (0.34–3.21) 2.17 (0.74–6.39) 1.00 (0.32–3.15)
> 15 cigarettes smoked 
per day
Case/control 15/38 *4/38 *10/38 4/10
OR (95% CI) 2.21 (0.67–7.28) 0.74 (0.07–7.94) 3.04 (0.71–13.0) 0.70 (0.14–3.50)
Smoking ≤ 30 years
Case/control *25/27 *9/123 *16/123 9/16
OR (95% CI) 1.74 (0.65–4.63) 0.07 (0.00–1.11) 1.59 (0.49–5.08) 0.99 (0.26–3.80)
Smoking > 30 years
Case/control 30/52 *8/52 *20/52 8/20
OR (95% CI) 2.86 (1.06–7.7) 2.45 (0.36–16.7) 4.06 (1.20–13.7) 0.77 (0.22–2.68)
Never smoked or starting 
smoking < 40 years ago§§
Case/control 42/306 *8/306 *28/306 8/28
Starting smoking ≥ 40 
years ago
Case/control 45/27 *17/27 *25/27 17/25
OR (95% CI) 1.10 (0.40–3.01) 2.0 (0.34–11.95) 0.93 (0.29–3.01) 2.24 (0.73–6.86)
*Missing values for smoking charactristics gave rise to diminished numbers of CRC cases.
§ Never smoked was used as reference category for "ever smoked", "dosage ≤ 15, > 15" and "duration ≤ 30, > 30".
§§ The combination of never smoked and starting smoking <40 years ago, was used as reference category for "starting smoking ≥ 40 years ago".
aAll the OR's are adjusted for age and sex.
bFor overall case-control comparison of CRC status and smoking, all the selected cases from the study population that had completed the 
questionnaire for smoking parameters were used.BMC Cancer 2006, 6:71 http://www.biomedcentral.com/1471-2407/6/71
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viously been associated with cigarette smoking and CRC
development [9-13]. The results may also indicate the
importance of the smoking parameter when evaluating
APC. If APC truncation mutations are involved in the ini-
tiating process, this association may be lost or diminished
when using a parameter without time frame of exposure.
For adenomatous polyps both latency period for ade-
noma development, and which ones will develop into
cancerous tumors is difficult to predict. It is interesting
that when comparing the adenoma and CRC case groups
to different smoking parameters, mean years since starting
smoking is the only parameter that is statistically signifi-
cantly different between the two case groups, P < 10-4.
Although, our adenoma case group is small, all have been
diagnosed with severe degree of dysplasia. The advanced
adenoma, defined by high-grade dysplasia, size > 1 cm or
villous features, has a greater potential of developing into
a cancerous tumor than small adenomas with mild or
moderate dysplasia [37].
For CRC cases divided based on APC truncation muta-
tional status all smoking parameters, except "starting
smoking ≥ 40 years ago", were associated with APC- cases.
For "duration of smoking > 30 years" this association was
statistically significant, OR = 4.06 (1.20–13.7). For APC +
cases no significant association was detected, but "dura-
tion of smoking > 30 years" and "starting smoking ≥ 40
years ago" showed an association. This may indicate that
cigarette smoking is associated with tumors without APC
truncation mutation, as reported in two previous pub-
lished studies by Diergaarde et al [11] and Lûchtenborg et
al [10]. These findings are comparable to the obtained
results for adenomas. As previously discussed, this may
imply the involvment of other genes in association with
cigarette smoking and colorectal carcinogenesis. Sporadic
CRC is a complex disease and several environmental fac-
tors in combination with genetic make up may have an
impact on CRC development. The chromosomal instabil-
ity (CIN) pathway involves several genes including APC,
k-ras and TP53 [14-16]. It has been reported that smoking
may be associated with k-ras transversion mutations and
play a role in TP53 negative tumors in CRC [11]. The other
major pathway for CRC development involves microsatel-
lite instability (MSI) [8]. Slattery et al reported that MSI
positive cases are more likely to smoke more than 20 sig-
arettes a day [9] and CRC tumors displaying MSI have
been positively associated with cigarette smoking.
However, smoking parameters like amount and duration
of smoking may not be the correct measures in validating
initiating causes for CRC development. Diergaarde et al
also reported a statistically significant inverse association
between CRC cases with APC truncation mutation and
"starting smoking ≤ 35 years ago" (OR 0.02, CI 0.1–0.8)
[11], and Lûchtenborg et al reported an inverse associa-
tion between "age first smoked ≥ 25 years" and CRC cases
with APC truncation mutation (OR 0.54, CI 0.26–1.10)
[10]. These results indicate that a sufficiently long time
since first exposed to cigarette smoke is important in order
to evaluate the association of smoking, APC mutation and
CRC development. For cigarette smoking to be the initiat-
ing factor a latency period of approximately 40 years has
been proposed [7]. In this study the case-case (APC+ ver-
sus APC-) comparison of CRC cases showed no associa-
tion or an inverse association for all smoking parameters,
except "starting smoking ≥ 40 years ago" with an OR =
2.24 (CI 0.73–6.86). This result is in concordance with
the theory of APC truncation mutations in the initiating
phases of CRC development. In addition, "starting smok-
ing ≥ 40 years ago" was the only smoking parameter that
was significantly different for APC + and APC- CRC cases,
P = 0.010. This parameter (starting smoking ≥ 40 years
ago) highlights the importance of the particular point in
time when starting smoking. There was no difference
between the two CRC subgroups when comparing dose
and duration.
Conclusion
Our results indicate that there is an association between
cigarette smoking and adenoma and CRC development.
For cases divided based on APC truncation mutation sta-
tus this association was strongest for cases without muta-
tion. This indicates that there are other factors that may
play a major role in development of these tumors. The
exception was for a smoking history with a time span of
40 years or more since first starting smoking. This smok-
ing parameter was only associated with cases with APC
mutations, though this association was not statistically
significant. This may suggest that smoking can contribute
to CRC development through mutations in the APC gene
if smoking starts prior to CRC initiation. A larger study
would be required to clarify this issue.
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